Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

April 12, 2018

CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. et al

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. September 17, 2020

    Bristol Myers, Dr. Reddy's Settle Revlimid Patent Suits

    Bristol-Myers Squibb unit Celgene will permit Dr. Reddy's Laboratories Ltd. to sell a generic version of its cancer drug Revlimid on a limited basis after March 2022 and then an unlimited amount in 2026, under a deal unveiled Thursday in Celgene's New Jersey federal suits alleging the Indian drugmaker infringed its patents.

1 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login